EP. 1: Individualizing Therapy for Multiple Myeloma Patients
Watch
EP. 2: Factoring Age Into Frontline Therapy for MM
EP. 3: Cost Considerations of Multidrug Regimens in MM
EP. 4: Achieving the Best Outcomes for Patients With MM
EP. 5: NCCN Guidelines for Newly Diagnosed MM
EP. 6: Considerations for Transplant-Ineligible Patients
EP. 7: Practical Implications of the MAIA Study for MM
EP. 8: Clinical Significance of MRD Testing in MM
EP. 9: Daratumumab in the Treatment Landscape for MM
EP. 10: What Is the Cost of Recurrence in Multiple Myeloma?
EP. 11: Initiating Treatment in Relapsed-Refractory MM
EP. 12: Dosing Strategies in Relapsed-Refractory MM
EP. 13: How Real-World Data Can Address Problems in MM
EP. 14: Backbone Therapy in Newly Diagnosed Multiple Myeloma
EP. 15: Strategy for Up-front Therapy of Multiple Myeloma
EP. 16: Impact of Maintenance Therapy in Multiple Myeloma
EP. 17: FORTE Trial: Transplant in Patients with Multiple Myeloma
EP. 18: Payer Perspective: Transplant and Toxicities in MM Therapy
EP. 19: Long-term Data on Improving OS for Patients With MM
EP. 20: Using MRD Negativity to Stop Maintenance Therapy in MM
EP. 21: MAIA Trial: Transplant-Ineligible Patients With MM
EP. 22: Entering a 4-Drug Regimen for Multiple Myeloma Treatment
EP. 23: The Impact of OCM in the Treatment of Multiple Myeloma
EP. 24: OCM Ensures Better Outcomes and Automatic Cost Savings in Multiple Myeloma
EP. 25: Reimbursement of Subcutaneous Versus IV Dosing in Multiple Myeloma
EP. 26: Treatment Options in Relapsed/Refractory Multiple Myeloma
EP. 27: Patient Cost Implications in Multiple Myeloma Treatment
EP. 28: Managing Discrepancies in NCCN and Payer Guidelines in Multiple Myeloma
EP. 29: Biochemical Versus Symptomatic Relapse Treatment Choices in MM
EP. 30: Final Thoughts on Approach to Multiple Myeloma Treatment
